LRP1 Inhibitors
LRP1 inhibitors, constituting a distinct chemical class, represent a specialized group of compounds meticulously designed to exert influence over the activity of low-density lipoprotein receptor-related protein 1 (LRP1). LRP1 is a multifaceted cell surface receptor intricately involved in diverse cellular processes, spanning endocytosis, intracellular signaling, and lipid metabolism. Its broad ligand-binding profile includes interactions with lipoproteins, proteases, growth factors, and extracellular matrix proteins, underlining its pivotal role in orchestrating cellular responses to extracellular cues. The primary objective of LRP1 inhibitors is to selectively modulate the functions of this versatile receptor and subsequently impact its associated downstream signaling pathways. Targeting LRP1 influences critical cellular processes, including the regulation of lipid uptake, clearance of proteases, and modulation of growth factor signaling. The nuanced design of these inhibitors reflects a keen understanding of the intricate molecular interactions that underlie LRP1's involvement in physiological and pathological processes.
Through the strategic inhibition of LRP1 activity, researchers aim to unravel the complexities of cellular regulation, offering a glimpse into the interconnected web of cellular responses governed by this receptor. The exploration of LRP1 inhibitors not only provides a means to decipher the intricate role of this receptor but also contributes to the broader understanding of cell surface receptor-ligand interactions. By dissecting the molecular mechanisms involved in LRP1 inhibition, researchers gain valuable insights into the manipulation of cellular responses in a controlled manner. The evolving landscape of LRP1 research underscores the importance of comprehending the molecular intricacies that govern cellular functions, paving the way for further advancements in the manipulation of cellular processes for scientific inquiry and applications in a variety of fields.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor, indirectly influencing LRP1 by modulating the mTORC1 pathway. mTORC1 activation can enhance LRP1 expression, so inhibition dampens this pathway, leading to reduced LRP1 activity. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Calcineurin inhibitor impacting NFAT signaling. LRP1 expression is regulated by NFAT, thus, inhibiting calcineurin suppresses NFAT activation, resulting in reduced LRP1 levels and downstream effects. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $127.00 $192.00 $269.00 $502.00 $717.00 $1380.00 $2050.00 | 114 | |
Selective STAT3 inhibitor affecting IL-6 signaling. LRP1 expression is linked to IL-6 signaling, so inhibiting STAT3 reduces IL-6-mediated effects, indirectly modulating LRP1 activity in specific cellular contexts. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor affecting Akt signaling. Akt activation is associated with increased LRP1 expression, thus, inhibiting PI3K with LY294002 may indirectly downregulate LRP1 levels through modulation of Akt signaling. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $153.00 $332.00 | 59 | |
JAK2 inhibitor influencing the JAK/STAT pathway. LRP1 expression can be influenced by JAK/STAT signaling, so inhibiting JAK2 with this compound may indirectly impact LRP1 levels through pathway modulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor impacting Akt signaling. Akt activation correlates with increased LRP1 expression; therefore, inhibiting PI3K with wortmannin may indirectly downregulate LRP1 levels through modulation of Akt signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the JNK pathway. LRP1 expression can be influenced by JNK signaling; thus, inhibiting JNK with SP600125 may indirectly impact LRP1 levels through modulation of the JNK pathway. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
NF-κB inhibitor impacting NF-κB signaling. LRP1 expression is regulated by NF-κB; therefore, inhibiting NF-κB with BAY 11-7082 may indirectly downregulate LRP1 levels through modulation of NF-κB signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor influencing the MAPK pathway. LRP1 modulation is observed downstream of MAPK signaling, making PD98059 a potential indirect inhibitor by suppressing the MAPK pathway and consequently LRP1 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor impacting the MAPK pathway. LRP1 modulation is observed downstream of MAPK signaling; hence, SB203580 may act as an indirect inhibitor by suppressing the p38 MAPK pathway and influencing LRP1. | ||||||